Hosted on MSN29d
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
BioMarin Pharmaceutical (BMRN) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank. Research ...
The Motley Fool1mon
BioMarin: EPS Surges Past Expectations
Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...
Zacks.com on MSN1mon
BioMarin to Report Q4 Earnings: Here's What to Expect
BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close ...
pharmaphorum5d
BioMarin gene therapy for haemophilia on course for EU approval
The EMA's human medicines advisory committee has recommended that BioMarin Pharmaceutical's haemophilia A gene therapy Roctavian be approved in the EU, removing one of the last barriers to launch.
Yahoo Finance1mon
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president and ...
Nasdaq1mon
BioMarin: EPS Surges Past Expectations
BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...